Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma

INTRODUCTION: Lenvatinib, a multiple receptor tyrosine kinase inhibitors that target vascular endothelial growth factor receptors and fibroblast growth factor receptors, recently demonstrated a treatment effect in various tumors. This study evaluated the efficacy and safety of lenvatinib for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunchao, Yang, Xiaobo, Wang, Dongxu, Yang, Xu, Wang, Yanyu, Long, Junyu, Zhou, Jinxue, Lu, Zhenhui, Mao, Yilei, Sang, Xinting, Guan, Mei, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928459/
https://www.ncbi.nlm.nih.gov/pubmed/35311147
http://dx.doi.org/10.3389/fonc.2022.785535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928459/
https://www.ncbi.nlm.nih.gov/pubmed/35311147
http://dx.doi.org/10.3389/fonc.2022.785535

Ejemplares similares